Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors

Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Mahito Ozawa, MD [verfasserIn] Takashi Komatsu, MD [verfasserIn] Hideaki Tachibana, MD [verfasserIn] Yoshihiro Sato, MD [verfasserIn] Makoto Orii, MD [verfasserIn] Fusanori Kunugita, MD [verfasserIn] Motoyuki Nakamura, MD [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2009

Schlagwörter:	Atrial fibrillation Thromboembolism Warfarin Aspirin

Übergeordnetes Werk:	In: Journal of Arrhythmia - Wiley, 2017, 25(2009), 2, Seite 81-88
Übergeordnetes Werk:	volume:25 ; year:2009 ; number:2 ; pages:81-88

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1016/S1880-4276(09)80021-5

Katalog-ID:	DOAJ072406046

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ072406046
003	DE-627
005	20230309110121.0
007	cr uuu---uuuuu
008	230228s2009 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/S1880-4276(09)80021-5 \|2 doi
035			\|a (DE-627)DOAJ072406046
035			\|a (DE-599)DOAJ521a09636da14659814af38e546fa4ab
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC666-701
100	0		\|a Mahito Ozawa, MD \|e verfasserin \|4 aut
245	1	0	\|a Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors
264		1	\|c 2009
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age.
650		4	\|a Atrial fibrillation
650		4	\|a Thromboembolism
650		4	\|a Warfarin
650		4	\|a Aspirin
653		0	\|a Diseases of the circulatory (Cardiovascular) system
700	0		\|a Takashi Komatsu, MD \|e verfasserin \|4 aut
700	0		\|a Hideaki Tachibana, MD \|e verfasserin \|4 aut
700	0		\|a Yoshihiro Sato, MD \|e verfasserin \|4 aut
700	0		\|a Makoto Orii, MD \|e verfasserin \|4 aut
700	0		\|a Fusanori Kunugita, MD \|e verfasserin \|4 aut
700	0		\|a Motoyuki Nakamura, MD \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Arrhythmia \|d Wiley, 2017 \|g 25(2009), 2, Seite 81-88 \|w (DE-627)733750141 \|w (DE-600)2696593-8 \|x 18832148 \|7 nnns
773	1	8	\|g volume:25 \|g year:2009 \|g number:2 \|g pages:81-88
856	4	0	\|u https://doi.org/10.1016/S1880-4276(09)80021-5 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/521a09636da14659814af38e546fa4ab \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S1880427609800215 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1880-4276 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 25 \|j 2009 \|e 2 \|h 81-88

Indexfelder

author_variant	o m m om omm k m t km kmt t m h tm tmh s m y sm smy o m m om omm k m f km kmf n m m nm nmm
matchkey_str	article:18832148:2009----::nihobtchrpacrigohgieieisebteaaeeicltosceynainsihovluaprxsaara
hierarchy_sort_str	2009
callnumber-subject-code	RC
publishDate	2009
allfields	10.1016/S1880-4276(09)80021-5 doi (DE-627)DOAJ072406046 (DE-599)DOAJ521a09636da14659814af38e546fa4ab DE-627 ger DE-627 rakwb eng RC666-701 Mahito Ozawa, MD verfasserin aut Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age. Atrial fibrillation Thromboembolism Warfarin Aspirin Diseases of the circulatory (Cardiovascular) system Takashi Komatsu, MD verfasserin aut Hideaki Tachibana, MD verfasserin aut Yoshihiro Sato, MD verfasserin aut Makoto Orii, MD verfasserin aut Fusanori Kunugita, MD verfasserin aut Motoyuki Nakamura, MD verfasserin aut In Journal of Arrhythmia Wiley, 2017 25(2009), 2, Seite 81-88 (DE-627)733750141 (DE-600)2696593-8 18832148 nnns volume:25 year:2009 number:2 pages:81-88 https://doi.org/10.1016/S1880-4276(09)80021-5 kostenfrei https://doaj.org/article/521a09636da14659814af38e546fa4ab kostenfrei http://www.sciencedirect.com/science/article/pii/S1880427609800215 kostenfrei https://doaj.org/toc/1880-4276 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 25 2009 2 81-88
spelling	10.1016/S1880-4276(09)80021-5 doi (DE-627)DOAJ072406046 (DE-599)DOAJ521a09636da14659814af38e546fa4ab DE-627 ger DE-627 rakwb eng RC666-701 Mahito Ozawa, MD verfasserin aut Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age. Atrial fibrillation Thromboembolism Warfarin Aspirin Diseases of the circulatory (Cardiovascular) system Takashi Komatsu, MD verfasserin aut Hideaki Tachibana, MD verfasserin aut Yoshihiro Sato, MD verfasserin aut Makoto Orii, MD verfasserin aut Fusanori Kunugita, MD verfasserin aut Motoyuki Nakamura, MD verfasserin aut In Journal of Arrhythmia Wiley, 2017 25(2009), 2, Seite 81-88 (DE-627)733750141 (DE-600)2696593-8 18832148 nnns volume:25 year:2009 number:2 pages:81-88 https://doi.org/10.1016/S1880-4276(09)80021-5 kostenfrei https://doaj.org/article/521a09636da14659814af38e546fa4ab kostenfrei http://www.sciencedirect.com/science/article/pii/S1880427609800215 kostenfrei https://doaj.org/toc/1880-4276 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 25 2009 2 81-88
allfields_unstemmed	10.1016/S1880-4276(09)80021-5 doi (DE-627)DOAJ072406046 (DE-599)DOAJ521a09636da14659814af38e546fa4ab DE-627 ger DE-627 rakwb eng RC666-701 Mahito Ozawa, MD verfasserin aut Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age. Atrial fibrillation Thromboembolism Warfarin Aspirin Diseases of the circulatory (Cardiovascular) system Takashi Komatsu, MD verfasserin aut Hideaki Tachibana, MD verfasserin aut Yoshihiro Sato, MD verfasserin aut Makoto Orii, MD verfasserin aut Fusanori Kunugita, MD verfasserin aut Motoyuki Nakamura, MD verfasserin aut In Journal of Arrhythmia Wiley, 2017 25(2009), 2, Seite 81-88 (DE-627)733750141 (DE-600)2696593-8 18832148 nnns volume:25 year:2009 number:2 pages:81-88 https://doi.org/10.1016/S1880-4276(09)80021-5 kostenfrei https://doaj.org/article/521a09636da14659814af38e546fa4ab kostenfrei http://www.sciencedirect.com/science/article/pii/S1880427609800215 kostenfrei https://doaj.org/toc/1880-4276 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 25 2009 2 81-88
allfieldsGer	10.1016/S1880-4276(09)80021-5 doi (DE-627)DOAJ072406046 (DE-599)DOAJ521a09636da14659814af38e546fa4ab DE-627 ger DE-627 rakwb eng RC666-701 Mahito Ozawa, MD verfasserin aut Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age. Atrial fibrillation Thromboembolism Warfarin Aspirin Diseases of the circulatory (Cardiovascular) system Takashi Komatsu, MD verfasserin aut Hideaki Tachibana, MD verfasserin aut Yoshihiro Sato, MD verfasserin aut Makoto Orii, MD verfasserin aut Fusanori Kunugita, MD verfasserin aut Motoyuki Nakamura, MD verfasserin aut In Journal of Arrhythmia Wiley, 2017 25(2009), 2, Seite 81-88 (DE-627)733750141 (DE-600)2696593-8 18832148 nnns volume:25 year:2009 number:2 pages:81-88 https://doi.org/10.1016/S1880-4276(09)80021-5 kostenfrei https://doaj.org/article/521a09636da14659814af38e546fa4ab kostenfrei http://www.sciencedirect.com/science/article/pii/S1880427609800215 kostenfrei https://doaj.org/toc/1880-4276 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 25 2009 2 81-88
allfieldsSound	10.1016/S1880-4276(09)80021-5 doi (DE-627)DOAJ072406046 (DE-599)DOAJ521a09636da14659814af38e546fa4ab DE-627 ger DE-627 rakwb eng RC666-701 Mahito Ozawa, MD verfasserin aut Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age. Atrial fibrillation Thromboembolism Warfarin Aspirin Diseases of the circulatory (Cardiovascular) system Takashi Komatsu, MD verfasserin aut Hideaki Tachibana, MD verfasserin aut Yoshihiro Sato, MD verfasserin aut Makoto Orii, MD verfasserin aut Fusanori Kunugita, MD verfasserin aut Motoyuki Nakamura, MD verfasserin aut In Journal of Arrhythmia Wiley, 2017 25(2009), 2, Seite 81-88 (DE-627)733750141 (DE-600)2696593-8 18832148 nnns volume:25 year:2009 number:2 pages:81-88 https://doi.org/10.1016/S1880-4276(09)80021-5 kostenfrei https://doaj.org/article/521a09636da14659814af38e546fa4ab kostenfrei http://www.sciencedirect.com/science/article/pii/S1880427609800215 kostenfrei https://doaj.org/toc/1880-4276 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 25 2009 2 81-88
language	English
source	In Journal of Arrhythmia 25(2009), 2, Seite 81-88 volume:25 year:2009 number:2 pages:81-88
sourceStr	In Journal of Arrhythmia 25(2009), 2, Seite 81-88 volume:25 year:2009 number:2 pages:81-88
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Atrial fibrillation Thromboembolism Warfarin Aspirin Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Journal of Arrhythmia
authorswithroles_txt_mv	Mahito Ozawa, MD @@aut@@ Takashi Komatsu, MD @@aut@@ Hideaki Tachibana, MD @@aut@@ Yoshihiro Sato, MD @@aut@@ Makoto Orii, MD @@aut@@ Fusanori Kunugita, MD @@aut@@ Motoyuki Nakamura, MD @@aut@@
publishDateDaySort_date	2009-01-01T00:00:00Z
hierarchy_top_id	733750141
id	DOAJ072406046
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ072406046</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309110121.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2009 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1880-4276(09)80021-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ072406046</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ521a09636da14659814af38e546fa4ab</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mahito Ozawa, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Atrial fibrillation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thromboembolism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Warfarin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Aspirin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takashi Komatsu, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hideaki Tachibana, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshihiro Sato, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Makoto Orii, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fusanori Kunugita, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Motoyuki Nakamura, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Arrhythmia</subfield><subfield code="d">Wiley, 2017</subfield><subfield code="g">25(2009), 2, Seite 81-88</subfield><subfield code="w">(DE-627)733750141</subfield><subfield code="w">(DE-600)2696593-8</subfield><subfield code="x">18832148</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:81-88</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1880-4276(09)80021-5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/521a09636da14659814af38e546fa4ab</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1880427609800215</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1880-4276</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2009</subfield><subfield code="e">2</subfield><subfield code="h">81-88</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Mahito Ozawa, MD
spellingShingle	Mahito Ozawa, MD misc RC666-701 misc Atrial fibrillation misc Thromboembolism misc Warfarin misc Aspirin misc Diseases of the circulatory (Cardiovascular) system Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors
authorStr	Mahito Ozawa, MD
ppnlink_with_tag_str_mv	@@773@@(DE-627)733750141
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	18832148
topic_title	RC666-701 Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors Atrial fibrillation Thromboembolism Warfarin Aspirin
topic	misc RC666-701 misc Atrial fibrillation misc Thromboembolism misc Warfarin misc Aspirin misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc Atrial fibrillation misc Thromboembolism misc Warfarin misc Aspirin misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc Atrial fibrillation misc Thromboembolism misc Warfarin misc Aspirin misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Arrhythmia
hierarchy_parent_id	733750141
hierarchy_top_title	Journal of Arrhythmia
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)733750141 (DE-600)2696593-8
title	Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors
ctrlnum	(DE-627)DOAJ072406046 (DE-599)DOAJ521a09636da14659814af38e546fa4ab
title_full	Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors
author_sort	Mahito Ozawa, MD
journal	Journal of Arrhythmia
journalStr	Journal of Arrhythmia
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2009
contenttype_str_mv	txt
container_start_page	81
author_browse	Mahito Ozawa, MD Takashi Komatsu, MD Hideaki Tachibana, MD Yoshihiro Sato, MD Makoto Orii, MD Fusanori Kunugita, MD Motoyuki Nakamura, MD
container_volume	25
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	Mahito Ozawa, MD
doi_str_mv	10.1016/S1880-4276(09)80021-5
author2-role	verfasserin
title_sort	antithrombotic therapy according to the guidelines issued by the japanese circulation society in patients with nonvalvular paroxysmal atrial fibrillation without thromboembolic risk factors
callnumber	RC666-701
title_auth	Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors
abstract	Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age.
abstractGer	Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age.
abstract_unstemmed	Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors
url	https://doi.org/10.1016/S1880-4276(09)80021-5 https://doaj.org/article/521a09636da14659814af38e546fa4ab http://www.sciencedirect.com/science/article/pii/S1880427609800215 https://doaj.org/toc/1880-4276
remote_bool	true
author2	Takashi Komatsu, MD Hideaki Tachibana, MD Yoshihiro Sato, MD Makoto Orii, MD Fusanori Kunugita, MD Motoyuki Nakamura, MD
author2Str	Takashi Komatsu, MD Hideaki Tachibana, MD Yoshihiro Sato, MD Makoto Orii, MD Fusanori Kunugita, MD Motoyuki Nakamura, MD
ppnlink	733750141
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1016/S1880-4276(09)80021-5
callnumber-a	RC666-701
up_date	2024-07-04T00:57:04.534Z
_version_	1803607997978509312
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ072406046</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309110121.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2009 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1880-4276(09)80021-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ072406046</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ521a09636da14659814af38e546fa4ab</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mahito Ozawa, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim and method: There have been few reports about the risk of ischemic stroke in elderly patients with non-valvular paroxysmal atrial fibrillation (NVPAF). The aim of this study was to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk evaluation was made based on the CHADS2 Score. However, we excluded age in this study, but included coronary disease. This study investigated a total of 150 patients with paroxysmal atrial fibrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean age 68 ± 12 years). The patients were divided into three groups according to age: the patients who were less than 60 years old (Group I, N = 58, Antithrombic therapy (+) = 18), those who were between 60 and 75 years old (Group II, N = 68, Antithrombic therapy (+) = 36) and those who were more than 75 years old (Group III, N = 24, Antithrombic therapy (+) = 7). The annual rates of thromboembolism among three groups were retrospectively analyzed. The mean follow-up periods were 56 ± 37 months. Results: (1) The annual rate of thromboembolism in Group III (4.0%) was significantly higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in Group II and 3.9% in Group III. The annual rate was significantly lower in Group II than in Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80- 100 mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a significant difference in the annual rate among the three groups (P < 0:05). (4) The annual rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in Group II and 0% in Group III (P = NS among 3 groups). Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke in patients with NVPAF regardless of their age.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Atrial fibrillation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thromboembolism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Warfarin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Aspirin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takashi Komatsu, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hideaki Tachibana, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshihiro Sato, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Makoto Orii, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fusanori Kunugita, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Motoyuki Nakamura, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Arrhythmia</subfield><subfield code="d">Wiley, 2017</subfield><subfield code="g">25(2009), 2, Seite 81-88</subfield><subfield code="w">(DE-627)733750141</subfield><subfield code="w">(DE-600)2696593-8</subfield><subfield code="x">18832148</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:81-88</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1880-4276(09)80021-5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/521a09636da14659814af38e546fa4ab</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1880427609800215</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1880-4276</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2009</subfield><subfield code="e">2</subfield><subfield code="h">81-88</subfield></datafield></record></collection>
score	7.4010725

Nicht das Richtige dabei?

Schreiben Sie uns!

Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?